Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04654221 · ClinicalTrials.gov registry record
Evaluation of Renal Function in Subjects Who Had Undergone Cardiac Surgery
A clinical trial, sponsored by Quark Pharmaceuticals.
- Terminated
- Registry status
- 16
- Enrollment target
NCT04654221 is a clinical trial that was terminated before completion, run by Quark Pharmaceuticals. The registered enrollment target is 16 participants.
The verdict
NCT04654221 was terminated before completion, sponsored by Quark Pharmaceuticals.
- TERMINATED
- Registry status
- 16 participants
- Enrollment target
Study Summary
To evaluate the differences between serum cystatin C based estimated glomerular filtration rate (eGFRcys), serum creatinine based eGFR (eGFRcreat) and measured glomerular filtration rate (mGFR) in subjects at high risk for acute kidney injury (AKI) approximately 90 days following cardiac surgery
Interventions
- DIAGNOSTIC_TEST mGFR by iohexol clearance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-02-21 |
| Est. Completion | 2021-03-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04654221
The ClinicalTrials.gov registry entry for NCT04654221 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Quark Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which mGFR by iohexol clearance is the first listed.
NCT04654221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04654221 about?
NCT04654221 is a clinical study titled "Evaluation of Renal Function in Subjects Who Had Undergone Cardiac Surgery". To evaluate the differences between serum cystatin C based estimated glomerular filtration rate (eGFRcys), serum creatinine based eGFR (eGFRcreat) and measured glomerular filtration rate (mGFR) in subjects at high risk for acute kidney injury (AKI) approximately 90 days following cardiac surgery
What is the current status of trial NCT04654221?
This trial is currently terminated. The enrollment target is 16 participants. The study started on 2020-02-21. Estimated completion is 2021-03-26.
What interventions are being tested in trial NCT04654221?
The interventions under investigation include: mGFR by iohexol clearance (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04654221?
This trial is sponsored by Quark Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.